A case of treatment-resistant membranous nephropathy associated with graft versus host disease successfully treated with daratumumab.

Published in: Pediatric transplantation (2022)

Daratumumab may be an important, novel therapeutic option for post-HCT MN patients who are not responsive to standard therapies.

Keyphrases